Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stiripentol.

Catherine Chiron1

  • 1Service de Neurologie et Metabolisme Hôpital Necker, INSERM U663, 149 rue de Sèvres, 75015 Paris, France. catherine.chiron@nck.aphp.fr

Expert Opinion on Investigational Drugs
|July 19, 2005
PubMed
Summary
This summary is machine-generated.

Stiripentol (STP), an aromatic allylic alcohol, shows efficacy in treating Dravet syndrome in children when combined with other antiepileptic drugs. Careful dose adjustment is needed due to its cytochrome P450 inhibitory effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Does Freediving Lead to Hippocampal Adaptability to Hypoxia and Maintenance of Episodic Memory?

Journal of integrative neuroscience·2025
Same author

Auditory evoked delta brushes involve stimulus-specific cortical networks in preterm infants.

iScience·2025
Same author

Cardiovascular and cerebral hemodynamics during static and dynamic breath-holding.

European journal of applied physiology·2025
Same author

Additional Results from Two Randomized, Placebo-Controlled Trials of Stiripentol in Dravet Syndrome Highlight a Rapid Antiseizure Efficacy with Longer Seizure-Free Periods.

Neurology and therapy·2024
Same author

Brain 18 F-FDG PET reveals cortico-subcortical hypermetabolic dysfunction in juvenile neuropsychiatric systemic lupus erythematosus.

EJNMMI research·2024
Same author

Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis.

Epilepsia open·2024
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Neurology
  • Clinical Trials

Background:

  • Stiripentol (STP) is a novel antiepileptic drug belonging to the aromatic allylic alcohol class.
  • It enhances GABAergic transmission but its development was hindered by cytochrome P450 (CYP) inhibition.
  • STP inhibits CYP3A4, CYP1A2, and CYP2C19 in epileptic patients.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of Stiripentol (STP) in specific pediatric epilepsy syndromes.
  • To assess the therapeutic potential of STP as an adjunctive therapy in treatment-resistant epilepsy.

Main Methods:

  • Clinical trials were conducted in pediatric populations with epilepsy, specifically Dravet syndrome.
  • Studies involved combining STP with established antiepileptic drugs like valproate and clobazam.

Related Experiment Videos

  • Controlled adjunctive-therapy trials were completed in pediatric epilepsy patients.

    • Main Results:

    • STP demonstrated specific efficacy in treating Dravet syndrome (severe myoclonic epilepsy in infancy) in pediatric patients.
    • Adjunctive therapy with STP, valproate, and clobazam proved beneficial.
    • Compassionate use data suggests potential benefits with carbamazepine in pharmacoresistant partial epilepsy.

    Conclusions:

    • Stiripentol is an effective adjunctive treatment for Dravet syndrome in children.
    • Drug interactions due to STP's CYP inhibition necessitate careful dose adjustments of co-administered antiepileptic drugs.
    • Orphan drug status was granted for STP in the EU for Dravet syndrome treatment.